LAM Therapeutics reports that the FDA has cleared LAM’s Investigational New Drug application for LAM-003 in leukemia patients. Identified by LAM’s technology platform in 2016, LAM-003 is a first-in-class immune-modulating drug for treating a genetically-defined population of acute myeloid leukemia patients.

Separately,  LAM-002 has transitioned into Phase 2 as a single agent and in combination with other therapies for treatment of B-cell non-Hodgkin lymphoma. LAM-002 is a first-in-class PIKfyve kinase inhibitor for B-cell malignancies.